The value of serum a-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy
1998

Measuring NaGalase Levels to Assess Tumor Response to Treatments

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): M Korbelik, VR Naraparaju, N Yamamoto

Primary Institution: British Columbia Cancer Agency; Albert Einstein Cancer Center

Hypothesis

How does the serum NaGalase activity reflect the response of tumors to radiotherapy and photodynamic therapy?

Conclusion

Serum NaGalase levels can effectively indicate tumor response to different cancer treatments.

Supporting Evidence

  • NaGalase levels increased with tumor growth and decreased after effective treatment.
  • Serum NaGalase activity was directly proportional to tumor burden.
  • Elevated NaGalase levels predicted tumor regrowth before visible recurrence.

Takeaway

This study shows that measuring a specific enzyme in the blood can help doctors understand how well cancer treatments are working.

Methodology

Mice with SCCVII tumors were treated with X-rays or photodynamic therapy, and serum NaGalase levels were measured over time.

Limitations

The study was conducted on mice, which may not fully represent human responses.

Participant Demographics

8- to 11-week-old female mice

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication